Review Article
No access
Published Online: 17 August 2020

Expanded Differentiation Capability of Human Wharton's Jelly Stem Cells Toward Pluripotency: A Systematic Review

Publication: Tissue Engineering Part B: Reviews
Volume 26, Issue Number 4

Abstract

Human Wharton's jelly stem cells (HWJSC) can be efficiently isolated from the umbilical cord, and numerous reports have demonstrated that these cells can differentiate into several cell lineages. This fact, coupled with the high proliferation potential of HWJSC, makes them a promising source of stem cells for use in tissue engineering and regenerative medicine. However, their real potentiality has not been established to date. In the present study, we carried out a systematic review to determine the multilineage differentiation potential of HWJSC. After a systematic literature search, we selected 32 publications focused on the differentiation potential of these cells. Analysis of these studies showed that HWJSC display expanded differentiation potential toward some cell types corresponding to all three embryonic cell layers (ectodermal, mesodermal, and endodermal), which is consistent with their constitutive expression of key pluripotency markers such as OCT4, SOX2, and NANOG, and the embryonic marker SSEA4. We conclude that HWJSC can be considered cells in an intermediate state between multipotentiality and pluripotentiality, since their proliferation capability is not unlimited and differentiation to all cell types has not been demonstrated thus far. These findings support the clinical use of HWJSC for the treatment of diseases affecting not only mesoderm-type tissues but also other cell lineages.

Impact statement

Human Wharton's jelly stem cells (HWJSC) are mesenchymal stem cells that are easy to isolate and handle, and that readily proliferate. Their wide range of differentiation capabilities supports the view that these cells can be considered pluripotent. Accordingly, HWJSC are one of the most promising cell sources for clinical applications in advanced therapies.

Get full access to this article

View all available purchase options and get full access to this article.

References

1. Hendijani, F., Sadeghi-Aliabadi, H., and Haghjooy Javanmard, S. Comparison of human mesenchymal stem cells isolated by explant culture method from entire umbilical cord and Wharton's jelly matrix. Cell Tissue Bank 15, 555, 2014.
2. Kalaszczynska, I., and Ferdyn, K. Wharton's jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance. Biomed Res Int 2015, 430847, 2015.
3. Pappa, K.I., and Anagnou, N. Novel sources of fetal stem cells: where do they fit on the developmental continuum? Regen Med 4, 423, 2009.
4. Chatzistamatiou, T.K., Papassavas, A.C., Michalopoulos, E., et al. Optimizing isolation culture and freezing methods to preserve Wharton's jelly's mesenchymal stem cell (MSC) properties: an MSC banking protocol validation for the Hellenic Cord Blood Bank. Transfusion 54, 3108, 2014.
5. Beeravolu, N., Khan, I., McKee, C., et al. Isolation and comparative analysis of potential stem/progenitor cells from different regions of human umbilical cord. Stem Cell Res 16, 696, 2016.
6. Yoon, J.H., Roh, E.Y., Shin, S., et al. Comparison of explant-derived and enzymatic digestion-derived MSCs and the growth factors from Wharton's jelly. Biomed Res Int 2013, 428726, 2013.
7. Salehinejad, P., Alitheen, N.B., Ali, A.M., et al. Comparison of different methods for the isolation of mesenchymal stem cells from human umbilical cord Wharton's jelly. In Vitro Cell Dev Biol Anim 48, 75, 2012.
8. Greco, S.J., Liu, K., and Rameshwar, P. Functional similarities among genes regulated by OCT4 in human mesenchymal and embryonic stem cells. Stem Cells 25, 3143, 2007.
9. Nekanti, U., Dastidar, S., Venugopal, P., Totey, S., and Ta, M. Increased proliferation and analysis of differential gene expression in human Wharton's jelly-derived mesenchymal stromal cells under hypoxia. Int J Biol Sci 6, 499, 2010.
10. Nekanti, U., Rao, V.B., Bahirvani, A.G., Jan, M., Totey, S., and Ta, M. Long-term expansion and pluripotent marker array analysis of Wharton's jelly-derived mesenchymal stem cells. Stem Cells Dev 19, 117, 2010.
11. Reppel, L., Margossian, T., Yaghi, L., et al. Hypoxic culture conditions for mesenchymal stromal/stem cells from Wharton's jelly: a critical parameter to consider in a therapeutic context. Curr Stem Cell Res Ther 9, 306, 2014.
12. Babaee, A., Nematollahi-Mahani, S.N., Shojaei, M., Dehghani-Soltani, S., and Ezzatabadipour, M. Effects of polarized and non-polarized red-light irradiation on proliferation of human Wharton's jelly-derived mesenchymal cells. Biochem Biophys Res Commun 504, 871, 2018.
13. Aubert, L., Dubus, M., Rammal, H., et al. Collagen-based medical device as a stem cell carrier for regenerative medicine. Int J Mol Sci 18, E2210, 2017.
14. Najar, M., Fayyad-Kazan, M., Meuleman, N., Bron, D., Fayyad-Kazan, H., and Lagneaux, L. Immunological impact of Wharton's Jelly mesenchymal stromal cells and natural killer cell co-culture. Mol Cell Biochem 447, 111, 2018.
15. Martin-Piedra, M.A., Alfonso-Rodriguez, C.A., Zapater, A., et al. Effective use of mesenchymal stem cells in human skin substitutes generated by tissue engineering. Eur Cell Mater 37, 233, 2019.
16. Teixeira, F.G., Carvalho, M.M., Neves-Carvalho, A., et al. Secretome of mesenchymal progenitors from the umbilical cord acts as modulator of neural/glial proliferation and differentiation. Stem Cell Rev Rep 11, 288, 2015.
17. Pires, A.O., Neves-Carvalho, A., Sousa, N., and Salgado, A.J. The secretome of bone marrow and Wharton jelly derived mesenchymal stem cells induces differentiation and neurite outgrowth in SH-SY5Y cells. Stem Cells Int 2014, 438352, 2014.
18. Hendijani, F., Javanmard, ShH., Rafiee, L., and Sadeghi-Aliabadi, H. Effect of human Wharton's jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells. Res Pharm Sci 10, 134, 2015.
19. Hendijani, F., Javanmard, S.H., and Sadeghi-aliabadi, H. Human Wharton's jelly mesenchymal stem cell secretome display antiproliferative effect on leukemia cell line and produce additive cytotoxic effect in combination with doxorubicin. Tissue Cell 47, 229, 2015.
20. Carvalho, M.M., Teixeira, F.G., Reis, R.L., Sousa, N., and Salgado, A.J. Mesenchymal stem cells in the umbilical cord: phenotypic characterization, secretome and applications in central nervous system regenerative medicine. Curr Stem Cell Res Ther 6, 221, 2011.
21. Bakhtyar, N., Jeschke, M.G., Herer, E., Sheikholeslam, M., and Amini-Nik, S. Exosomes from acellular Wharton's jelly of the human umbilical cord promotes skin wound healing. Stem Cell Res Ther 9, 193, 2018.
22. Dormer, N.H., Singh, M., Zhao, L., Mohan, N., Berkland, C.J., and Detamore, M.S. Osteochondral interface regeneration of the rabbit knee with macroscopic gradients of bioactive signals. J Biomed Mater Res Part A 100A, 162, 2012.
23. Gauthaman, K., Fong, C.Y., Venugopal, J.R., Biswas, A., Ramakrishna, S., and Bongso, A. Propagation and differentiation of human Wharton's jelly stem cells on three-dimensional nanofibrous scaffolds. Methods Mol Biol 1058, 1, 2013.
24. Garzon, I., Alfonso-Rodriguez, C.A., Martinez-Gomez, C., et al. Expression of epithelial markers by human umbilical cord stem cells. A topographical analysis. Placenta 35, 994, 2014.
25. Varaa, N., Azandeh, S., Khorsandi, L., Bijan Nejad, D., Bayati, V., and Bahreini, A. Ameliorating effect of encapsulated hepatocyte-like cells derived from umbilical cord in high mannuronic alginate scaffolds on acute liver failure in rats. Iran J Basic Med Sci 21, 928, 2018.
26. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6, e1000097, 2009.
27. Fong, C.Y., Tam, K., Cheyyatraivendran, S., et al. Human Wharton's jelly stem cells and its conditioned medium enhance healing of excisional and diabetic wounds. J Cell Biochem 115, 290, 2014.
28. Tam, K., Cheyyatraviendran, S., Venugopal, J., et al. A nanoscaffold impregnated with human Wharton's jelly stem cells or its secretions improves healing of wounds. J Cell Biochem 115, 794, 2014.
29. Garzon, I., Martin-Piedra, M.A., Alfonso-Rodriguez, C., et al. Generation of a biomimetic human artificial cornea model using Wharton's jelly mesenchymal stem cells. Invest Ophthalmol Vis Sci 55, 4073, 2014.
30. Garzon, I., Miyake, J., Gonzalez-Andrades, M., et al. Wharton's jelly stem cells: a novel cell source for oral mucosa and skin epithelia regeneration. Stem Cells Transl Med 2, 625, 2013.
31. Dos Santos, A., Balayan, A., Funderburgh, M.L., Ngo, J., Funderburgh, J.L., and Deng, S.X. Differentiation capacity of human mesenchymal stem cells into keratocyte lineage. Invest Ophthalmol Vis Sci 60, 3013, 2019.
32. Karamichos, D., Rich, C.B., Hutcheon, A.E., et al. Self-assembled matrix by umbilical cord stem cells. J Funct Biomater 2, 213, 2011.
33. Khatami, S.M., Zahri, S., Maleki, M., and Hamidi, K. Stem cell isolation from human Wharton's jelly: a study of their differentiation ability into lens fiber cells. Cell J 15, 364, 2014.
34. Davis, H., Guo, X.F., Lambert, S., Stancescu, M., and Hickman, J.J. Small molecule induction of human umbilical stem cells into myelin basic protein positive oligodendrocytes in a defined three-dimensional environment. ACS Chem Neurosci 3, 31, 2012.
35. Omar, N., Lokanathan, Y., Mohd Razi, Z.R., and Bt Haji Idrus, R. The effects of Centella asiatica (L.) urban on neural differentiation of human mesenchymal stem cells in vitro. BMC Complement Altern Med 19, 167, 2019.
36. Fong, C.Y., Biswas, A., Subramanian, A., Srinivasan, A., Choolani, M., and Bongso, A. Human keloid cell characterization and inhibition of growth with human Wharton's jelly stem cell extracts. J Cell Biochem 115, 826, 2014.
37. Gage, P.J., Rhoades, W., Prucka, S.K., and Hjalt, T. Fate maps of neural crest and mesoderm in the mammalian eye. Invest Ophthalmol Vis Sci 46, 4200, 2005.
38. Cortes-Medina, L.V., Pasantes-Morales, H., Aguilera-Castrejon, A., et al. Neuronal transdifferentiation potential of human mesenchymal stem cells from neonatal and adult sources by a small molecule cocktail. Stem Cells Int 2019, 7627148, 2019.
39. Datta, I., Mishra, S., Mohanty, L., Pulikkot, S., and Joshi, P.G. Neuronal plasticity of human Wharton's jelly mesenchymal stromal cells to the dopaminergic cell type compared with human bone marrow mesenchymal stromal cells. Cytotherapy 13, 918, 2011.
40. Tantrawatpan, C., Manochantr, S., Kheolamai, P., U-Pratya, Y., Supokawej, A., and Issaragrisil, S. Pluripotent gene expression in mesenchymal stem cells from human umbilical cord Wharton's jelly and their differentiation potential to neural-like cells. J Med Assoc Thai 96, 1208, 2013.
41. Pereira, R.C., Costa-Pinto, A.R., Frias, A.M., Neves, N.M., Azevedo, H.S., and Reis, R.L. In vitro chondrogenic commitment of human Wharton's jelly stem cells by co-culture with human articular chondrocytes. J Tissue Eng Regen Med 11, 1876, 2017.
42. Wang, H., Yan, X., Jiang, Y., Wang, Z., Li, Y., and Shao, Q. The human umbilical cord stem cells improve the viability of OA degenerated chondrocytes. Mol Med Rep 17, 4474, 2018.
43. Ramesh, A., Kanafi, M.M., and Bhonde, R.R. Modulus-dependent characteristics of Wharton's jelly mesenchymal stem cells (WJMSC) encapsulated in hydrogel microspheres. J Biomater Sci Polym Ed 25, 1946, 2014.
44. Wajid, N., Mehmood, A., Bhatti, F.U.R., Khan, S.N., and Riazuddin, S. Lovastatin protects chondrocytes derived from Wharton's jelly of human cord against hydrogen-peroxide-induced in vitro injury. Cell Tissue Res 351, 433, 2013.
45. Alami, S.M., Rammal, H., Boulagnon-Rombi, C., et al. Harnessing Wharton's jelly stem cell differentiation into bone-like nodule on calcium phosphate substrate without osteoinductive factors. Acta Biomater 49, 575, 2017.
46. da Silva, M.A., Martins, A., Costa-Pinto, A.R., et al. Electrospun nanofibrous meshes cultured with Wharton's jelly stem cell: an alternative for cartilage regeneration, without the need of growth factors. Biotechnol J 12, 9, 2017.
47. Witkowska-Zimny, M., Walenko, K., Walkiewicz, A.E., Pojda, Z., Przybylski, J., and Lewandowska-Szumiel, M. Effect of substrate stiffness on differentiation of umbilical cord stem cells. Acta Biochim Pol 59, 261, 2012.
48. Alami, S.M., Velard, F., Draux, F., et al. Gene screening of Wharton's jelly derived stem cells. Bio-Med Mater Eng 24, S53, 2014.
49. Chen, W., Zhou, H., Weir, M.D., Bao, C., and Xu, H.H. Umbilical cord stem cells released from alginate-fibrin microbeads inside macroporous and biofunctionalized calcium phosphate cement for bone regeneration. Acta Biomater 8, 2297, 2012.
50. Zhao, L., Weir, M.D., and Xu, H.H.K. Human umbilical cord stem cell encapsulation in calcium phosphate scaffolds for bone engineering. Biomaterials 31, 3848, 2010.
51. Thein-Han, W., Liu, J., and Xu, H.H.K. Calcium phosphate cement with biofunctional agents and stem cell seeding for dental and craniofacial bone repair. Dent Mater 28, 1059, 2012.
52. Zhao, L.A., Weir, M.D., and Xu, H.H.K. An injectable calcium phosphate-alginate hydrogel-umbilical cord mesenchymal stem cell paste for bone tissue engineering. Biomaterials 31, 6502, 2010.
53. Thein-Han, W., and Xu, H.H. Collagen-calcium phosphate cement scaffolds seeded with umbilical cord stem cells for bone tissue engineering. Tissue Eng Part A 17, 2943, 2011.
54. Fong, C.Y., Subramanian, A., Gauthaman, K., et al. Human umbilical cord Wharton's jelly stem cells undergo enhanced chondrogenic differentiation when grown on nanofibrous scaffolds and in a sequential two-stage culture medium environment. Stem Cell Rev 8, 195, 2012.
55. Gauthaman, K., Venugopal, J.R., Yee, F.C., Biswas, A., Ramakrishna, S., and Bongso, A. Osteogenic differentiation of human Wharton's jelly stem cells on nanofibrous substrates in vitro. Tissue Eng Part A 17, 71, 2011.
56. Dormer, N.H., Singh, M., Wang, L.M., Berkland, C.J., and Detamore, M.S. Osteochondral interface tissue engineering using macroscopic gradients of bioactive signals. Ann Biomed Eng 38, 2167, 2010.
57. Alaminos, M., Perez-Kohler, B., Garzon, I., et al. Transdifferentiation potentiality of human Wharton's jelly stem cells towards vascular endothelial cells. J Cell Physiol 223, 640, 2010.
58. Vico, M., Rodriguez-Morata, A., Garzon, I., et al. Cell viability evaluation of transdifferentiated endothelial-like cells by quantitative electron-probe X-ray microanalysis for tissue engineering. Histol Histopathol 30, 1333, 2015.
59. Wu, K.H., Mo, X.M., Zhou, B., et al. Cardiac potential of stem cells from whole human umbilical cord tissue. J Cell Biochem 107, 926, 2009.
60. Christman, J.K. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21, 5483, 2002.
61. Lin, S.Z., Chang, Y.J., Liu, J.W., et al. Transplantation of human Wharton's jelly-derived stem cells alleviates chemically induced liver fibrosis in rats. Cell Transplant 19, 1451, 2010.
62. Dominici, M., Le Blanc, K., Mueller, I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315, 2006.
63. Bhuvanalakshmi, G., Arfuso, F., Kumar, A.P., Dharmarajan, A., and Warrier, S. Epigenetic reprogramming converts human Wharton's jelly mesenchymal stem cells into functional cardiomyocytes by differential regulation of Wnt mediators. Stem Cell Res Ther 8, 185, 2017.
64. Lange, C., Cakiroglu, F., Spiess, A.N., Cappallo-Obermann, H., Dierlamm, J., and Zander, A.R. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J Cell Physiol 213, 18, 2007.
65. Garzon, I., Perez-Kohler, B., Garrido-Gomez, J., et al. Evaluation of the cell viability of human Wharton's jelly stem cells for use in cell therapy. Tissue Eng Part C Methods 18, 408, 2012.
66. Nikitina, V., Astrelina, T., Nugis, V., et al. Clonal chromosomal and genomic instability during human multipotent mesenchymal stromal cells long-term culture. PLoS One 13, e0192445, 2018.
67. Gatta, V., D'Aurora, M., Lanuti, P., et al. Gene expression modifications in Wharton's Jelly mesenchymal stem cells promoted by prolonged in vitro culturing. BMC Genomics 14, 635, 2013.
68. Hao, H., Chen, G., Liu, J., et al. Culturing on Wharton's jelly extract delays mesenchymal stem cell senescence through p53 and p16INK4a/pRb pathways. PLoS One 8, e58314, 2013.
69. Li, M., and Belmonte, J.C. Ground rules of the pluripotency gene regulatory network. Nat Rev Genet 18, 180, 2017.
70. Bhartiya, D. Intricacies of Pluripotency. J Stem Cells Regen Med 11, 2, 2015.
71. Avilion, A.A., Nicolis, S.K., Pevny, L.H., Perez, L., Vivian, N., and Lovell-Badge, R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 17, 126, 2003.
72. Masui, S., Nakatake, Y., Toyooka, Y., et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9, 625, 2007.
73. Niwa, H., Miyazaki, J., and Smith, A.G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24, 372, 2000.
74. Thomson, M., Liu, S.J., Zou, L.N., Smith, Z., Meissner, A., and Ramanathan, S. Pluripotency factors in embryonic stem cells regulate differentiation into germ layers. Cell 145, 875, 2011.
75. Bonilla-Porras, A.R., Velez-Pardo, C., and Jimenez-Del-Rio, M. Fast transdifferentiation of human Wharton's jelly mesenchymal stem cells into neurospheres and nerve-like cells. J Neurosci Methods 282, 52, 2017.

Information & Authors

Information

Published In

cover image Tissue Engineering Part B: Reviews
Tissue Engineering Part B: Reviews
Volume 26Issue Number 4August 2020
Pages: 301 - 312
PubMed: 32085697

History

Published online: 17 August 2020
Published in print: August 2020
Published ahead of print: 20 March 2020
Published ahead of production: 21 February 2020
Accepted: 14 February 2020
Received: 25 September 2019

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Ingrid Garzon [email protected]
Tissue Engineering Group, Department of Histology, School of Medicine, University of Granada, Granada, Spain.
ibs.GRANADA, Biohealth Institute, Granada, Spain.
Jesus Chato-Astrain
Tissue Engineering Group, Department of Histology, School of Medicine, University of Granada, Granada, Spain.
ibs.GRANADA, Biohealth Institute, Granada, Spain.
Fernando Campos
Tissue Engineering Group, Department of Histology, School of Medicine, University of Granada, Granada, Spain.
ibs.GRANADA, Biohealth Institute, Granada, Spain.
Ricardo Fernandez-Valades
ibs.GRANADA, Biohealth Institute, Granada, Spain.
Division of Pediatric Surgery, University of Granada Hospital Complex, Granada, Spain.
Indalecio Sanchez-Montesinos
ibs.GRANADA, Biohealth Institute, Granada, Spain.
Department of Human Anatomy and Embryology, School of Medicine, University of Granada, Granada, Spain.
Antonio Campos
Tissue Engineering Group, Department of Histology, School of Medicine, University of Granada, Granada, Spain.
ibs.GRANADA, Biohealth Institute, Granada, Spain.
Miguel Alaminos
Tissue Engineering Group, Department of Histology, School of Medicine, University of Granada, Granada, Spain.
ibs.GRANADA, Biohealth Institute, Granada, Spain.
Rena N. D'Souza
Department of Dentistry, School of Dentistry, University of Utah, Salt Lake City, Utah, USA.
Miguel A. Martin-Piedra
Tissue Engineering Group, Department of Histology, School of Medicine, University of Granada, Granada, Spain.
ibs.GRANADA, Biohealth Institute, Granada, Spain.

Notes

Address correspondence to: Ingrid Garzon, OD, PhD, Tissue Engineering Group, Department of Histology, School of Medicine, University of Granada, Avenida de la Investigación 11, 5A, Granada 18071, Spain [email protected]

Disclosure Statement

No competing financial interests exist.

Funding Information

This study was supported by the Spanish Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (I+D+I) of the Spanish Ministry of Economy and Competitiveness (Instituto de Salud Carlos III), grants FIS PI17/0391, PI18/331, and PI18/332 (cofinanced by ERDF-FEDER, European Union).

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top